TG
COLL icon

TLP Group’s Collegium Pharmaceutical COLL Stock Holding History

TLP Group’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,500
Closed -$164K – 283
2016
Q3 		$164K Buy
+8,500
New +$101K 0.17% 94

Other funds holding COLL

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

TLP Group's COLL Position: Q4 2016 in Review

TLP Group sold out of Collegium Pharmaceutical (COLL) in Q4 2016, closing a stake of 8,500 shares — an estimated $164K sold.

TLP Group first reported a position in COLL in Q3 2016 and held it in 1 quarter. The position peaked at $164K in Q3 2016. 88 funds tracked by Wall St. Rank hold COLL as of Q4 2016.

  • TLP Group reported no remaining Collegium Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • TLP Group sold 8,500 Collegium Pharmaceutical shares in Q4 2016, an estimated $164K.
  • TLP Group first reported a position in Collegium Pharmaceutical in Q3 2016 and held it in 1 quarter.
  • TLP Group's Collegium Pharmaceutical position peaked at $164K in Q3 2016.
  • 88 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.